Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAF(V600)-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor

PURPOSE: Preclinical and early clinical studies have demonstrated that initial therapy with combined BRAF and MEK inhibition is more effective in BRAF(V600)-mutant melanoma than single-agent BRAF inhibitors. This study assessed the safety and efficacy of dabrafenib and trametinib in patients who had...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Clin Oncol
Hauptverfasser: Johnson, Douglas B., Flaherty, Keith T., Weber, Jeffrey S., Infante, Jeffrey R., Kim, Kevin B., Kefford, Richard F., Hamid, Omid, Schuchter, Lynn, Cebon, Jonathan, Sharfman, William H., McWilliams, Robert R., Sznol, Mario, Lawrence, Donald P., Gibney, Geoffrey T., Burris, Howard A., Falchook, Gerald S., Algazi, Alain, Lewis, Karl, Long, Georgina V., Patel, Kiran, Ibrahim, Nageatte, Sun, Peng, Little, Shonda, Cunningham, Elizabeth, Sosman, Jeffrey A., Daud, Adil, Gonzalez, Rene
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Clinical Oncology 2014
Schlagworte:
ORIGINAL REPORTS
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4226803/
https://ncbi.nlm.nih.gov/pubmed/25287827
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.57.3535
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge